EWING, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its third quarter 2016 financial results and recent operating progress before the market opens on Wednesday, November 9, 2016. Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on November 9, 2016 to discuss the results. Interested parties may participate in the conference call by dialing 1-888-280-4443 (U.S.) or 1-719-457-2653 (international) and entering access code 3270156. We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time. A replay of the conference call will be available from 11:30 a.m. ET on Wednesday, November 9, 2016 through 11:30 a.m. ET on Friday, December 9, 2016 by dialing 1-888-203-1112 (U.S.) or 1-719-457-0820 (international), and entering the access code 3270156. An audio web cast and archive of the conference call will also be available under the investor information section of the Antares Web site at www.antarespharma.com. About Antares Pharma Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company's product, OTREXUP™ (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company and Teva Pharmaceutical Industries, Ltd. (Teva) recently announced the commercial launch of VIBEX ® Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in the United States. Antares Pharma is also developing QuickShot ® Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX ® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva that includes VIBEX ® epinephrine, exenatide multi-dose pen, and teriparatide multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V. The Company is also working with AMAG Pharmaceuticals on a subcutaneous method of administering Makena, a progesterone product indicated for use in lowering the risk of pre-term birth. For more information, visit www.antarespharma.com.